Poly(ADP-ribose) polymerase (PARP) inhibitors constitute the inaugural targeted therapy shown to enhance the prognosis of individuals with hereditary tumors, initially utilized in the management of patients with germline <i>BRCA1/2-</i>associated breast cancer. Here, BRCA1 is linked to breast carcinoma.